ISPOR - Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) with Nilotinib as the Second-Line Treatment in Russian Federation

Full Text

Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) with Nilotinib as the Second-Line Treatment in Russian Federation

Abstract

Authors

VG Serpik R Yagudina

Back to Volume 18, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now